HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Xunming Ji Selected Research

N,N,N',N'- tetrakis(2- pyridylmethyl)ethylenediamine

11/2016Zinc contributes to acute cerebral ischemia-induced blood-brain barrier disruption.
10/2015Reduction of zinc accumulation in mitochondria contributes to decreased cerebral ischemic injury by normobaric hyperoxia treatment in an experimental stroke model.
4/2014Chelating intracellularly accumulated zinc decreased ischemic brain injury through reducing neuronal apoptotic death.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Xunming Ji Research Topics

Disease

116Stroke (Strokes)
12/2022 - 01/2006
96Ischemic Stroke
12/2022 - 02/2009
55Ischemia
10/2022 - 01/2007
51Brain Ischemia (Cerebral Ischemia)
10/2022 - 01/2006
49Infarction (Infarctions)
01/2022 - 08/2008
29Middle Cerebral Artery Infarction (Middle Cerebral Artery Syndrome)
01/2021 - 05/2009
26Hypothermia
01/2021 - 01/2007
24Brain Injuries (Brain Injury)
11/2021 - 01/2007
18Reperfusion Injury
01/2021 - 06/2011
14Cerebral Infarction
01/2022 - 01/2006
13Cerebral Hemorrhage
01/2022 - 02/2009
12Hypoxia (Hypoxemia)
10/2022 - 09/2011
12Inflammation (Inflammations)
06/2022 - 02/2010
10Hemorrhage
06/2022 - 01/2009
10Pathologic Constriction (Stenosis)
06/2022 - 01/2009
10Thrombosis (Thrombus)
06/2022 - 11/2007
8Atherosclerosis
01/2022 - 05/2016
8Neoplasms (Cancer)
01/2022 - 01/2009
6Hyperoxia
10/2022 - 01/2013
6Hypertension (High Blood Pressure)
02/2022 - 01/2009
6Hemorrhagic Stroke
01/2021 - 03/2012
6Edema (Dropsy)
01/2020 - 02/2012
5Intracranial Hemorrhages (Intracranial Hemorrhage)
01/2022 - 10/2018
5Intracranial Arteriosclerosis (Cerebral Atherosclerosis)
01/2022 - 01/2009
5Necrosis
01/2021 - 01/2013
5Brain Edema (Cerebral Edema)
01/2016 - 02/2012
4Venous Thrombosis (Deep-Vein Thrombosis)
06/2022 - 01/2018
4Hyperhomocysteinemia
02/2022 - 05/2016
4Cerebrovascular Disorders (Cerebrovascular Occlusion)
12/2021 - 03/2009
4Headache (Headaches)
01/2021 - 01/2018
4Glioma (Gliomas)
01/2021 - 02/2010
4Neurodegenerative Diseases (Neurodegenerative Disease)
10/2019 - 02/2010
4Intracranial Sinus Thrombosis (Sinus Thrombosis)
10/2018 - 05/2013
4Transient Ischemic Attack
04/2017 - 05/2009
3Vascular Diseases (Vascular Disease)
02/2022 - 08/2018
3Atherosclerotic Plaque (Atheroma)
01/2022 - 07/2017
3Heart Diseases (Heart Disease)
01/2022 - 01/2013
3Brain Infarction
01/2021 - 01/2012
3Myocardial Infarction
01/2019 - 02/2017
3Wounds and Injuries (Trauma)
01/2018 - 01/2016

Drug/Important Bio-Agent (IBA)

31Neuroprotective AgentsIBA
10/2022 - 01/2007
30Oxygen (Dioxygen)IBA
10/2022 - 05/2011
28Proteins (Proteins, Gene)FDA Link
10/2022 - 01/2007
22Biomarkers (Surrogate Marker)IBA
10/2022 - 01/2006
16Tissue Plasminogen Activator (Alteplase)FDA Link
01/2020 - 02/2009
15salicylhydroxamic acid (SHAM)IBA
07/2021 - 06/2011
13Glucose (Dextrose)FDA LinkGeneric
12/2021 - 05/2009
11Pharmaceutical PreparationsIBA
12/2022 - 05/2009
10MicroRNAs (MicroRNA)IBA
01/2021 - 06/2013
9Ethanol (Ethyl Alcohol)IBA
01/2017 - 01/2012
8Reactive Oxygen Species (Oxygen Radicals)IBA
09/2019 - 08/2014
7CytokinesIBA
12/2021 - 03/2014
7Therapeutic UsesIBA
01/2021 - 02/2010
7ErythropoietinFDA Link
01/2016 - 05/2009
6OccludinIBA
02/2021 - 11/2015
6AntioxidantsIBA
01/2021 - 10/2010
6Evans Blue (Blue, Evans)FDA Link
01/2020 - 06/2011
6Messenger RNA (mRNA)IBA
06/2018 - 08/2008
6Small Interfering RNA (siRNA)IBA
06/2018 - 06/2011
6Urokinase-Type Plasminogen Activator (Urokinase)FDA Link
01/2018 - 01/2006
5oxidized low density lipoproteinIBA
12/2021 - 09/2016
5ZincIBA
01/2019 - 04/2014
4CholesterolIBA
02/2022 - 09/2016
4Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA
02/2022 - 04/2019
4LipidsIBA
01/2022 - 07/2017
4Matrix Metalloproteinase 9 (Gelatinase B)IBA
02/2021 - 03/2009
4C-Reactive ProteinIBA
02/2021 - 06/2011
4Eosine Yellowish-(YS) (Eosin)IBA
01/2020 - 08/2008
4Hematoxylin (Haematoxylon)IBA
01/2020 - 08/2008
4Matrix Metalloproteinases (MMPs)IBA
01/2020 - 01/2009
4fibrin fragment D (D-dimer)IBA
01/2020 - 05/2009
4Fibrinogen (Factor I)FDA Link
08/2019 - 06/2011
4IceIBA
08/2018 - 06/2016
4TOR Serine-Threonine KinasesIBA
01/2018 - 12/2013
4Chlorpromazine (Thorazine)FDA Link
12/2017 - 05/2015
4Promethazine (Promet)FDA LinkGeneric
12/2017 - 05/2015
4Collagenases (Collagenase)FDA Link
01/2016 - 05/2011
3Transcription Factors (Transcription Factor)IBA
01/2022 - 02/2015
3Adenosine (Adenocard)FDA LinkGeneric
01/2022 - 05/2009
3Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA
12/2021 - 10/2016
3LigandsIBA
11/2021 - 01/2018
3Tirofiban (Aggrastat)FDA Link
08/2021 - 12/2017
3Glial Fibrillary Acidic ProteinIBA
02/2021 - 01/2018
3Claudin-5IBA
02/2021 - 01/2016
3Caspase 3 (Caspase-3)IBA
01/2020 - 10/2010
3Chelating AgentsIBA
01/2018 - 10/2015
3ChloridesIBA
06/2017 - 05/2009
3N,N,N',N'- tetrakis(2- pyridylmethyl)ethylenediamineIBA
11/2016 - 04/2014
3DNA (Deoxyribonucleic Acid)IBA
05/2016 - 01/2007

Therapy/Procedure

73Therapeutics
12/2022 - 12/2002
21Thrombectomy
12/2022 - 05/2013
16Induced Hypothermia
01/2022 - 05/2009
14Ischemic Postconditioning
07/2021 - 06/2011
8Stents
06/2022 - 01/2009
6Intra-Arterial Infusions
01/2016 - 06/2011
5Catheters
01/2022 - 01/2009
3Activities of Daily Living (ADL)
01/2020 - 01/2013
3Transplantation
12/2019 - 01/2014
3Intraperitoneal Injections
01/2018 - 02/2015
3Aftercare (After-Treatment)
01/2018 - 02/2009